Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to cut arthritis flares by tailoring drug tapering

NCT ID NCT06528431

Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized approach to slowly reduce the dose of the biologic drug adalimumab in people with rheumatoid arthritis who are in remission. The goal is to find the best blood level of the drug before each dose reduction to lower the risk of disease flares. 180 adults with stable RA will be followed to see if this tailored tapering strategy works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years of age * Patients with a diagnosis of RA according to ACR/EULAR 2010 criteria * Remission according to DAS28\<=2.6 for at least 6 months * Patient treated with ADA for at least 6 months. The patient is treated according to one of the following two strategies: * ADA 40 mg every two weeks (= every 14 days) according to the standard regimen * or ADA 40 mg every 3 weeks (= every 21 days) * A negative highly sensitive pregnancy test for women of Childbearing Potential\* * Affiliated person or beneficiary of a social security scheme * Informed consent signed by the patient after information Exclusion Criteria: * Incapacity or refusal to understand and / or sign informed consent to participate in the study. * Existing pregnancy, lactation, or intended pregnancy within the next 15 months * Fibromyalgia associated to RA * Any dose of prednisone for RA treatment 6 months before inclusion * Patient deprived of liberty or patient under guardianship or curator ship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis rheumatoid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis rheumatoid

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ap-Hp Pitie Salpetriere

    RECRUITING

    Paris, 75013, France

  • Chd Vendee

    RECRUITING

    La Roche-sur-Yon, 85925, France

  • Chru Tours

    NOT_YET_RECRUITING

    Tours, 37170, France

  • Chu Montpellier

    RECRUITING

    Montpellier, 34295, France

  • Chu Reims

    NOT_YET_RECRUITING

    Reims, 51100, France

  • Chu Saint Etienne

    RECRUITING

    Saint-Etienne, 42055, France

  • Hopital Philibert

    RECRUITING

    Lomme, 59160, France

  • Infirmerie Protestante

    RECRUITING

    Caluire-et-Cuire, 69300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.